- Library Home /
- Search Collections /
- Open Collections /
- Browse Collections /
- UBC Faculty Research and Publications /
- Serum IgG subclass levels and risk of exacerbations...
Open Collections
UBC Faculty Research and Publications
Serum IgG subclass levels and risk of exacerbations and hospitalizations in patients with COPD Leitao Filho, Fernando S.; Ra, Seung W; Mattman, Andre; Schellenberg, Robert; Criner, Gerard J.; Woodruff, Prescott G.; Lazarus, Stephen C.; Albert, Richard; Connett, John E.; Han, Meilan K.; Martinez, Fernando J.; Leung, Janice M.; Man, S. F. P.; Aaron, Shawn D.; Reed, Robert M.; Sin, Don D.
Abstract
Background: The literature is scarce regarding the prevalence and clinical impact of IgG subclass deficiency in COPD. We investigated the prevalence of IgG subclass deficiencies and their association with exacerbations and hospitalizations using subjects from two COPD cohorts. Methods: We measured IgG subclass levels using immunonephelometry in serum samples from participants enrolled in two previous COPD trials: Macrolide Azithromycin for Prevention of Exacerbations of COPD (MACRO; n = 976) and Simvastatin for the Prevention of Exacerbations in Moderate-to-Severe COPD (STATCOPE; n = 653). All samples were collected from clinically stable participants upon entry into both studies. IgG subclass deficiency was diagnosed when IgG subclass levels were below their respective lower limit of normal: IgG1
Item Metadata
Title |
Serum IgG subclass levels and risk of exacerbations and hospitalizations in patients with COPD
|
Creator | |
Contributor | |
Publisher |
BioMed Central
|
Date Issued |
2018-02-14
|
Description |
Background:
The literature is scarce regarding the prevalence and clinical impact of IgG subclass deficiency in COPD. We investigated the prevalence of IgG subclass deficiencies and their association with exacerbations and hospitalizations using subjects from two COPD cohorts.
Methods:
We measured IgG subclass levels using immunonephelometry in serum samples from participants enrolled in two previous COPD trials: Macrolide Azithromycin for Prevention of Exacerbations of COPD (MACRO; n = 976) and Simvastatin for the Prevention of Exacerbations in Moderate-to-Severe COPD (STATCOPE; n = 653). All samples were collected from clinically stable participants upon entry into both studies. IgG subclass deficiency was diagnosed when IgG subclass levels were below their respective lower limit of normal: IgG1
|
Subject | |
Genre | |
Type | |
Language |
eng
|
Date Available |
2018-02-14
|
Provider |
Vancouver : University of British Columbia Library
|
Rights |
Attribution 4.0 International (CC BY 4.0)
|
DOI |
10.14288/1.0363887
|
URI | |
Affiliation | |
Citation |
Respiratory Research. 2018 Feb 14;19(1):30
|
Publisher DOI |
10.1186/s12931-018-0733-z
|
Peer Review Status |
Reviewed
|
Scholarly Level |
Faculty
|
Copyright Holder |
The Author(s).
|
Rights URI | |
Aggregated Source Repository |
DSpace
|
Item Media
Item Citations and Data
Rights
Attribution 4.0 International (CC BY 4.0)